RxDoctor Payments Data

Prashant Atri, MD

Interventional Cardiology · Tacoma, WANPI 1497984918

Payments from drug & device makers

What this record shows

16 manufacturers reported payments, led by Edwards Lifesciences at 46.3% of the total.

$6,165in general payments, 2019–2025

Across 68 payments — averaging $90.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$3K
  • Abbott$2K
  • Boston Scientific$346
  • Abiomed$196
  • Shockwave Medical, Inc$86
  • Johnson & Johnson$81
  • plus $214 from 10 others

What the payments were for

  • Travel & lodging$3,54557%
  • Food & beverage$2,62143%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,165 in reported general payments places this provider in the 60th percentile of 125 interventional cardiology providers in Washington.

See all interventional cardiology providers in Washington

Medicare billing

Part B allowed, 2024
$187,707
Medicare patients
705
Services billed
1,492

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban216$227,777
XareltoRivaroxaban120$109,766
Repatha SureclickEvolocumab22$17,878
BrilintaTicagrelor12$14,622
Metoprolol Succinate368$4,344
Atorvastatin Calcium359$3,586
ClopidogrelClopidogrel Bisulfate174$1,732
Isosorbide Mononitrate ErIsosorbide Mononitrate112$1,354
Carvedilol145$1,279
Diltiazem 24hr Er (Xr)Diltiazem Hcl39$1,132
Dilt-XrDiltiazem Hcl27$1,094
Rosuvastatin Calcium72$1,055
Amlodipine Besylate204$979
Potassium Chloride49$938
Losartan Potassium113$882

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$81$109,766120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 125 interventional cardiology providers in Washington.

Other interventional cardiology in Tacoma

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →